Skip to Main content Skip to Navigation
Journal articles

Fibrates, glitazones, and peroxisome proliferator-activated receptors.

Abstract : Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 diabetes mellitus. Relatively recently, these drugs were found to act via peroxisome proliferator-activated receptors, nuclear receptors that control lipid metabolism and glucose homeostasis. In this historical perspective, we discuss the history of discovery of the peroxisome proliferator-activated receptors, from the clinical development of their agonists to the subsequent discovery of these receptors and their mechanisms of action, to finally evoke possibilities of targeted pharmacology for future development of selective peroxisome proliferator-activated receptor modulators.
Document type :
Journal articles
Complete list of metadatas

Cited literature [25 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00475566
Contributor : Marie-Hélène Derudas <>
Submitted on : Tuesday, November 2, 2010 - 11:14:28 AM
Last modification on : Wednesday, October 21, 2020 - 3:42:00 AM
Long-term archiving on: : Thursday, February 3, 2011 - 2:35:21 AM

Files

inserm-00475566_edited.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Fanny Lalloyer, Bart Staels. Fibrates, glitazones, and peroxisome proliferator-activated receptors.. Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association, 2010, 30 (5), pp.894-9. ⟨10.1161/ATVBAHA.108.179689⟩. ⟨inserm-00475566⟩

Share

Metrics

Record views

211

Files downloads

1356